MDS and AML MATTER

Clinicians specializing in pathology and hematology/oncology face challenges in managing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), similar but distinct blood cancers associated with significant morbidity and mortality that affect many patients in the Unites States (US).  The project Myelodysplastic Syndrome and Acute Myeloid Leukemia MATTER: Multidisciplinary Approach To Testing and Diagnosis, Evaluation of Risk, and Personalized Treatment Selection is designed to meet the needs of multidisciplinary care teams on the optimal diagnosis and classification of both MDS and AML, in addition to addressing issues of risk stratification and individualized treatment selection, assessment of treatment responses, monitoring for and mitigation of adverse events, and hear from patients and caregivers regarding their journey.